Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma
暂无分享,去创建一个
H. Sagara | H. Tillmann | C. Gessner | R. V. van Zyl-Smit | M. Hosoe | A. Pethe | P. D’Andrea | H. Kerstjens | K. Chapman | A. Tănase | D. Lawrence
[1] Rajesh Venkitakrishnan,et al. Inhaled steroid - Long acting beta two agonist (ICS-LABA) combinations in asthma: Are all formulations the same? , 2021, The Indian journal of tuberculosis.
[2] N. Scichilone,et al. Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma , 2021, Expert review of respiratory medicine.
[3] D. Hinds,et al. A systematic literature review of burden of illness in adults with uncontrolled moderate/severe asthma. , 2021, Respiratory medicine.
[4] H. Kerstjens,et al. Evaluating contributions of mometasone (MF), indacaterol (IND) and glycopyrronium (GLY) to reduction of exacerbations in patients with inadequately controlled asthma: Results from the IRIDIUM study , 2021, Airway pharmacology and treatment.
[5] H. Kerstjens,et al. One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies , 2021, BMJ Open Respiratory Research.
[6] H. Inoue,et al. Uncontrolled asthma: a retrospective cohort study in Japanese patients newly prescribed with medium-/high-dose ICS/LABA , 2021, npj Primary Care Respiratory Medicine.
[7] H. Kerstjens,et al. Corresponding doses of mometasone furoate (MF) in once-daily inhaled fixed-dose combination (FDC) of indacaterol/mometasone furoate (IND/MF) and indacaterol/glycopyrronium/mometasone furoate (IND/GLY/MF): results from randomized clinical studies , 2021 .
[8] O. Heudi,et al. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects , 2021, BMC Pulmonary Medicine.
[9] O. Heudi,et al. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects. , 2020, Pulmonary pharmacology & therapeutics.
[10] I. Pavord,et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. , 2020, The Lancet. Respiratory medicine.
[11] C. Gessner,et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON). , 2020, Respiratory medicine.
[12] H. Kerstjens,et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. , 2020, The Lancet. Respiratory medicine.
[13] Y. Gon,et al. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study. , 2020, The Lancet. Respiratory medicine.
[14] H. Watz,et al. Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study , 2020, Respiratory Research.
[15] A. Ismaila,et al. Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review , 2020, International journal of chronic obstructive pulmonary disease.
[16] P. D’Andrea,et al. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings. , 2020, Respiratory medicine.
[17] J. Virchow,et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials , 2019, The Lancet.
[18] R. Stanford,et al. Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs , 2019, The Journal of asthma : official journal of the Association for the Care of Asthma.
[19] M. Adachi,et al. Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. , 2019, Allergology international : official journal of the Japanese Society of Allergology.
[20] R. D. Dal Negro,et al. Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma , 2018, Multidisciplinary Respiratory Medicine.
[21] K. Greive,et al. Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids , 2018, The Australasian journal of dermatology.
[22] F. Güldaval,et al. Assessment of osteoporosis using the FRAX method and the importance of vitamin D levels in COPD patients , 2018, Multidisciplinary Respiratory Medicine.
[23] M. Cazzola,et al. Fixed-Dose Combination Inhalers. , 2016, Handbook of experimental pharmacology.
[24] H. Nelson,et al. Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial , 2015, BMJ Open.
[25] R. Dahl,et al. Turning a Molecule into a Medicine: the Development of Indacaterol as a Novel Once-Daily Bronchodilator Treatment for Patients with COPD , 2014, Drugs.
[26] Michael Engel,et al. Tiotropium in asthma poorly controlled with standard combination therapy. , 2012, The New England journal of medicine.
[27] S. Keam,et al. Salmeterol/Fluticasone Propionate , 2012, Drugs.
[28] R. Leigh,et al. Mometasone furoate: an inhaled glucocorticoid for the management of asthma in adults and children , 2009, Expert opinion on pharmacotherapy.
[29] A. van As,et al. Indacaterol, a novel inhaled β2-agonist, provides sustained 24-h bronchodilation in asthma , 2007, European Respiratory Journal.
[30] H. Derendorf,et al. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. , 2005, Immunology and allergy clinics of North America.
[31] H. Nelson,et al. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. , 2003, The Journal of allergy and clinical immunology.
[32] O. Zetterström,et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. , 2001, The European respiratory journal.
[33] R. Pauwels,et al. GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .